Ash 2021 roundup
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Data in sickle cell disease look encouraging, but a filing is a way away.
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
The early movers could point to a disappointing meeting.